Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inosi IRAP inhibitor
- Development stage
- Preclinical
- Lead developer
- Inosi Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intracranial, Intracerebroventricular, Intraperitoneal, Intratracheal, Intravenous, Rectal, Intranasal, Topical, Buccal, Sublingual, Vaginal, Intramuscular, Parenteral
01
Overview
Inosi IRAP inhibitor is a novel small molecule inhibitor of Insulin-Regulated Aminopeptidase (IRAP, also known as LNPEP) being developed by Inosi Therapeutics for the treatment of various fibrotic diseases. IRAP is an enzyme found at elevated levels in diseased heart and kidney tissues, particularly in the context of diabetes and cardiovascular conditions. By inhibiting this enzyme, the drug demonstrates anti-fibrotic effects, with preclinical evidence showing it can reverse established fibrosis and improve organ function across several models, including cardiac, renal, lung, and liver fibrosis. The program originated from collaborative research at Monash University and is currently in IND-enabling studies, targeting indications such as chronic kidney disease, diabetic kidney disease, idiopathic pulmonary fibrosis, and nonalcoholic steatohepatitis (NASH).
- Other names
- IRAP inhibitoranti-fibrotic programLNPEP inhibitor
02
Targets
LNPEP (Leucyl/cystinyl aminopeptidase)
Beyond the preview
Go deeper on Inosi IRAP inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inosi IRAP inhibitor.